Characterizing the next generation of bioconjugates

Join leading voices from across the biopharmaceutical industry as they discuss the analytical and bioanalytical challenges shaping the next generation of bioconjugate therapeutics.

As the field expands beyond traditional antibody-drug conjugates (ADCs) to include increasingly complex modalities, such as antibody-oligonucleotide conjugates (AOCs), bispecific ADCs, and dual-payload constructs, development teams need a more integrated understanding of molecular attributes, product heterogeneity, stability, and behavior in biological systems.

In this SelectScience® Accelerating Science Forum, experts from across the development pathway will explore how characterization and bioanalytical strategies are evolving in response to this complexity. The panel will consider how CMC, PK, and bioanalytical evidence can be connected to support informed decisions from molecular design and early development through manufacturing.

Attend this online roundtable discussion to:

• Explore how next-generation bioconjugate formats are changing analytical and bioanalytical requirements
• Gain insights into evaluating critical quality attributes, heterogeneity, stability, and clinically relevant species
• Understand how CMC, PK, and bioanalytical evidence can inform development and manufacturing decisions
• Hear expert perspectives on the capabilities needed to support future bioconjugate modalities

Certificate of attendance

If you attend the live event, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand recording, you can request a certificate of attendance by emailing [email protected].

Forum details

• Cost: Free to attend
• Location: Online
• Duration: 60 mins

Registration is required to access this Accelerating Science Forum. If you missed the live broadcast, register now to watch the recording.

What will this webinar cover?

• Understand how emerging bioconjugate formats are changing analytical and bioanalytical requirements
• Explore the challenges of evaluating product quality, heterogeneity, stability, and clinically relevant species
• Learn how CMC, PK, and bioanalytical evidence can inform molecular design and development decisions
• Consider the capabilities and cross-functional approaches needed to support future bioconjugate modalities

Presenter: Sara Carillo, PhD (Principal Scientist, Senior Manager, NationalBioprocessing Research and Training (NIBRT))

Sara Carillo earned her Ph.D. in chemical sciences from the University of Naples Federico II, where she studied polysaccharides and glycoconjugates using NMR and mass spectrometry. She joined NIBRT in 2015 and is nowPrincipal Scientist, developing MS-based methods to better characterize biomanufacturing processes and biopharmaceutical complexity.

Presenter: Dr. Jim Shen (Executive Director, Bioanalysis and Translational Mass Spectrometry, Bristol Myers Squibb)

Presenter: Dr. Fabio Rossi (Director of Analytics, Abzena)

Presenter: Richard Linkous (Analytical Scientist, AstraZeneca)

Moderator: Cameron Smith-Craig (Pharma and Applied Sciences Editor, SelectScience)